Answers are grounded in this paper and cite their sources.
Early and accurate diagnosis of Alzheimer's disease (AD) is necessary to enable timely intervention. Some of the traditional tests, such as positron emission tomography (PET) scans and cerebrospinal fluid (CSF) punctures, are too expensive or invasive and thus not been widely used. This review systematically evaluates the clinical progress of research on plasma phosphorylated tau 217 (p-tau217). The aim is to know if p-tau217 can be used as an early marker for the start of mild cognitive impairment (MCI) in brains of older adults. According to the current data, plasma p-tau217 have good diagnostic ability for early-stage Alzheimer's disease and can be used in a "two-cutoff" method at the clinic. Therefore, non-AD patients do not need to be included in the primary care area, and high-risk individuals in special memory clinics can be identified to reduce the number of expensive PET and CSF tests. However, it still has many problems in clinical use. In short, although plasma p-tau217 is a promising non-invasive early detection method, healthcare professionals should still consider all the circumstances in the overall health status of each patient before making any decisions.
No takes yet. Share an insight, caveat, or question.
Anqi Gong (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: